Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on February 17, 2021, reporting an event that occurred on the same date. The company is a clinical-stage biopharmaceutical firm focused on developing novel therapies for cancer.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material change reported is a clinical development milestone:
- Completion of the dose-escalation stage for the Company's ongoing Phase 1/2 clinical trial.
- Establishment of the recommended Phase 2 dose for the treatment of relapsed/refractory Ewing sarcoma.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the clinical progress. No specific financial guidance or forward-looking revenue projections are included in this text.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the inherent uncertainties of clinical trials implied by the ongoing nature of the Phase 1/2 study.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for specific details on the recommended Phase 2 dose and safety data.
- Confirm the timeline for the initiation of the Phase 2 expansion cohort.
- Review the company's most recent 10-K or 10-Q for current cash runway and burn rate, as this 8-K contains no financial data.